华森制药（002907）7月29日主力资金净流入6726.09万元

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Huason Pharmaceutical, indicating a positive trend in stock price and trading volume [1] - As of July 29, 2025, Huason Pharmaceutical's stock closed at 18.51 yuan, reflecting a 6.5% increase with a trading volume of 378,300 lots and a transaction amount of 687 million yuan [1] - The net inflow of main funds was 67.26 million yuan, accounting for 9.79% of the transaction amount, with significant contributions from large orders [1] Group 2 - For the first quarter of 2025, Huason Pharmaceutical reported total operating revenue of 239 million yuan, a year-on-year increase of 4.62%, and a net profit attributable to shareholders of 40.36 million yuan, showing a slight increase of 0.01% [1] - The company has a current ratio of 5.198, a quick ratio of 4.589, and a debt-to-asset ratio of 12.95%, indicating strong liquidity and low leverage [1] - Huason Pharmaceutical, established in 1996 and based in Chongqing, has a registered capital of 4.18 billion yuan and a paid-in capital of 777 million yuan [1] Group 3 - Huason Pharmaceutical has made investments in 12 companies and participated in 4,241 bidding projects, showcasing its active engagement in the market [2] - The company holds 204 trademark registrations and 135 patents, along with 210 administrative licenses, reflecting its commitment to intellectual property and regulatory compliance [2]